Eupraxia Pharmaceuticals Inc.
EPRX.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$382.02M
Close$
$2.01
81.1% downside
Current Fair Value
81.1% downsideOvervalued by 81.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $382.02 Million |
|---|---|
| Enterprise Value | $331.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.05 |
| Beta | 1.49 |
| Outstanding Shares | 66,221,815 |
Return
| Return on Equity | -45.08% |
|---|---|
| Return on Assets | -42.30% |
| Return on Invested Capital | -47.52% |
Valuation & Multiples
| P/E Ratio | -7.31 |
|---|---|
| PEG | -11.17 |
| Price to Sales | - |
| Price to Book Ratio | 10.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.32 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eupraxia Pharmaceuticals Inc
49 employees
CEO: James A. Helliwell Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical ...